FTC, Memory-Booster Co. Spar Over Errors At 2nd. Circ.

By Dani Kass (June 22, 2018, 7:28 PM EDT) -- Quincy Bioscience and the Federal Trade Commission have been sparring at the Second Circuit over how the company should handle fixing misstatements about a clinical trial for its contested memory booster Prevagen, with the agency accusing the supplement maker of flouting "proper appellate litigation" by just correcting its brief....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!